EMEA-001760-PIP01-15-M02

  • Email
  • Help

Overview

Product details for Lartruvo
Invented nameLartruvo
Active substance

Olaratumab

Decision numberP/0139/2017
PIP numberEMEA-001760-PIP01-15-M02
Pharmaceutical form(s)Concentrate for solution for infusion
Condition(s)/indication(s)

Treatment of osteosarcoma

Treatment of soft tissue sarcoma

Route(s) of administrationIntravenous use
PIP applicant

Eli Lilly and Company Limited
United Kingdom
Tel. +44 1276483000
E-mail: eu_paediatric@lilly.com

Decision typePM: decision on the application for modification of an agreed PIP

Decision